Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer

Simon A. Jones, Brendan J. Jenkins

Research output: Contribution to journalReview ArticleResearchpeer-review

34 Citations (Scopus)

Abstract

The IL-6 family of cytokines consists of IL-6, IL-11, IL-27, IL-31, oncostatin M (OSM), leukaemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), cardiotrophin 1 (CT-1) and cardiotrophin-like cytokine factor 1 (CLCF1). Membership of this cytokine family is defined by usage of common β-receptor signalling subunits, which activate various intracellular signalling pathways. Each IL-6 family member elicits responses essential to the physiological control of immune homeostasis, haematopoiesis, inflammation, development and metabolism. Accordingly, distortion of these cytokine activities often promotes chronic disease and cancer; the pathological importance of this is exemplified by the successful treatment of certain autoimmune conditions with drugs that target the IL-6 pathway. Here, we discuss the emerging roles for IL-6 family members in infection, chronic inflammation, autoimmunity and cancer and review therapeutic strategies designed to manipulate these cytokines in disease.

Original languageEnglish
Pages (from-to)773-789
Number of pages17
JournalNature Reviews Immunology
Volume18
Issue number12
DOIs
Publication statusPublished - 1 Dec 2018

Cite this

@article{202821fb9c60409d9c544bb76c2ec9fb,
title = "Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer",
abstract = "The IL-6 family of cytokines consists of IL-6, IL-11, IL-27, IL-31, oncostatin M (OSM), leukaemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), cardiotrophin 1 (CT-1) and cardiotrophin-like cytokine factor 1 (CLCF1). Membership of this cytokine family is defined by usage of common β-receptor signalling subunits, which activate various intracellular signalling pathways. Each IL-6 family member elicits responses essential to the physiological control of immune homeostasis, haematopoiesis, inflammation, development and metabolism. Accordingly, distortion of these cytokine activities often promotes chronic disease and cancer; the pathological importance of this is exemplified by the successful treatment of certain autoimmune conditions with drugs that target the IL-6 pathway. Here, we discuss the emerging roles for IL-6 family members in infection, chronic inflammation, autoimmunity and cancer and review therapeutic strategies designed to manipulate these cytokines in disease.",
author = "Jones, {Simon A.} and Jenkins, {Brendan J.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41577-018-0066-7",
language = "English",
volume = "18",
pages = "773--789",
journal = "Nature Reviews Immunology",
issn = "1474-1733",
publisher = "Nature Publishing Group",
number = "12",

}

Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. / Jones, Simon A.; Jenkins, Brendan J.

In: Nature Reviews Immunology, Vol. 18, No. 12, 01.12.2018, p. 773-789.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer

AU - Jones, Simon A.

AU - Jenkins, Brendan J.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - The IL-6 family of cytokines consists of IL-6, IL-11, IL-27, IL-31, oncostatin M (OSM), leukaemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), cardiotrophin 1 (CT-1) and cardiotrophin-like cytokine factor 1 (CLCF1). Membership of this cytokine family is defined by usage of common β-receptor signalling subunits, which activate various intracellular signalling pathways. Each IL-6 family member elicits responses essential to the physiological control of immune homeostasis, haematopoiesis, inflammation, development and metabolism. Accordingly, distortion of these cytokine activities often promotes chronic disease and cancer; the pathological importance of this is exemplified by the successful treatment of certain autoimmune conditions with drugs that target the IL-6 pathway. Here, we discuss the emerging roles for IL-6 family members in infection, chronic inflammation, autoimmunity and cancer and review therapeutic strategies designed to manipulate these cytokines in disease.

AB - The IL-6 family of cytokines consists of IL-6, IL-11, IL-27, IL-31, oncostatin M (OSM), leukaemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), cardiotrophin 1 (CT-1) and cardiotrophin-like cytokine factor 1 (CLCF1). Membership of this cytokine family is defined by usage of common β-receptor signalling subunits, which activate various intracellular signalling pathways. Each IL-6 family member elicits responses essential to the physiological control of immune homeostasis, haematopoiesis, inflammation, development and metabolism. Accordingly, distortion of these cytokine activities often promotes chronic disease and cancer; the pathological importance of this is exemplified by the successful treatment of certain autoimmune conditions with drugs that target the IL-6 pathway. Here, we discuss the emerging roles for IL-6 family members in infection, chronic inflammation, autoimmunity and cancer and review therapeutic strategies designed to manipulate these cytokines in disease.

UR - http://www.scopus.com/inward/record.url?scp=85053838588&partnerID=8YFLogxK

U2 - 10.1038/s41577-018-0066-7

DO - 10.1038/s41577-018-0066-7

M3 - Review Article

VL - 18

SP - 773

EP - 789

JO - Nature Reviews Immunology

JF - Nature Reviews Immunology

SN - 1474-1733

IS - 12

ER -